Macroautophagy is thought to protect against apoptosis; however, underlying mechanisms are poorly understood. We examined how autophagy affects canonical death receptor-induced mitochondrial outer membrane permeabilization (MOMP) and apoptosis. MOMP occurs at variable times in a population of cells, and this is delayed by autophagy. Additionally, autophagy leads to inefficient MOMP, after which some cells die through a slower process than typical apoptosis and, surprisingly, can recover and divide afterward. These effects are associated with p62/SQSTM1-dependent selective autophagy causing PUMA levels to be kept low through an indirect mechanism whereby autophagy affects constitutive levels of PUMA mRNA. PUMA depletion is sufficient to prevent the sensitization to apoptosis that occurs when autophagy is blocked. Autophagy can therefore control apoptosis via a key regulator that makes MOMP faster and more efficient, thus ensuring rapid completion of apoptosis. This identifies a molecular mechanism whereby cell-fate decisions can be determined by autophagy.
INTRODUCTION
Macroautophagy and apoptosis are closely linked (Gump and Thorburn, 2011; Maiuri et al., 2007b; Rubinstein and Kimchi, 2012) . Molecular mechanisms whereby autophagy can promote apoptosis in response to specific stimuli have been identified in Drosophila (Nezis et al., 2010) and, more recently, in mammalian cells (Gump et al., 2014) . However, because autophagy is primarily a prosurvival mechanism, it is generally thought that the two processes regulate each other in opposite directions. Distinct molecular mechanisms have been identified whereby apoptosis can inhibit autophagy. For example, caspases cleave autophagy regulators such as Beclin 1 (BECN1) to suppress autophagy (Cho et al., 2009; Li et al., 2011; Luo and Rubinsztein, 2010) . In contrast, mechanisms by which autophagy protects against apoptosis are poorly understood. The simplest way that autophagy can protect against apoptosis is by modulating the stresses that activate the apoptosis machinery. For example, autophagy protects against nutrient and growth-factor-deprivation-induced apoptosis (Boya et al., 2005; Lum et al., 2005) . However, this need not mean that autophagy inhibits the core apoptosis machinery; instead, degradation of cellular components by autophagy can supply macromolecular precursors and energy until nutrients are restored, and this might avoid activation of apoptosis signaling at all. Although many proteins regulate both autophagy and apoptosis (Gump and Thorburn, 2011; Rubinstein and Kimchi, 2012) , general mechanisms by which the process of autophagy controls the core apoptosis machinery have not been identified. Nevertheless, because diverse apoptotic stimuli (e.g., different classes of chemotherapy drugs; Levy and Thorburn, 2011) can all be sensitized when autophagy is inhibited, it is widely suggested that regulation of the core apoptosis machinery by autophagy must exist.
Even when cells in a clonal population die in response to a defined stimulus, there is considerable variation in the timing of apoptosis (Albeck et al., 2008; Goldstein et al., 2000; Spencer et al., 2009 ). Single-cell imaging of well-understood apoptosis stimuli such as the Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) have shown how this cell-to-cell variation comes about. TRAIL induces apoptosis in most cells via ''Type II apoptosis'' whereby TRAIL receptor signaling leads to activation of caspase-8, which cleaves the BH3 domain-containing protein BID to create a truncated protein called tBID. tBID translocates to mitochondria causing BAX-and BAK-dependent permeabilization of the outer mitochondrial membrane releasing cytochrome c, Smac/Diablo, and other mitochondrial proteins. Mitochondrial Outer Membrane Permeabilization (MOMP) is completed within a few minutes (Goldstein et al., 2000; Rehm et al., 2003) and is widely considered a point of no return that marks commitment to death because it is followed within 5-10 min by a burst of effector caspase activity that causes rapid contraction and fragmentation of the cell. The variation in timing of apoptosis is due to variation in the time when MOMP occurs and has been extensively studied in TRAIL-treated HeLa cells (Albeck et al., 2008; Spencer et al., 2009) .
Here, we examined the effects of autophagy on this wellunderstood canonical apoptosis pathway. We found that autophagy controls the core apoptosis machinery by regulating the timing of MOMP and the cell response after MOMP. These effects can be explained by autophagy's ability to regulate low constitutive levels of the BH3 domain-containing protein PUMA. Surprisingly, autophagy's effects on PUMA can also lead to slow and incomplete cellular degradation after MOMP from which some cells can recover and go on to divide and the proapoptotic effect of autophagy inhibition on viability of cells after apoptosis stimulation is blocked by removal of PUMA. This defines a mechanism by which autophagy can control the apoptotic threshold to govern cell fate.
RESULTS AND DISCUSSION

Timing of MOMP Is Regulated by Autophagy
We treated HeLa cells with TRAIL and monitored MOMP using time-lapse microscopy to determine when a mitochondrial-targeted Red Fluorescent Protein (Albeck et al., 2008) was released into the cytoplasm. Autophagy was increased by treatment with trehalose, which activates autophagy via an mTOR-independent mechanism (Sarkar et al., 2007) and, unlike other autophagy stimulators like mTOR inhibitors or starvation, has no known other effects on cell viability. Autophagy was inhibited by RNAi knockdown of essential autophagy regulators such as ATG12 as shown by reduced accumulation of LC3-II in cells where autophagic flux was blocked ( Figure 1A ). As expected (Albeck et al., 2008) , MOMP was completed within 5 min ( Figure 1B ) starting at variable times ( Figure 1C ) from approximately 50 min to over 2 hr following treatment with TRAIL at doses sufficient to induce MOMP in all the cells in the population. Trehalose-treated cells still underwent MOMP; however, its timing was markedly delayed when autophagy was stimulated. This delay was blocked when autophagy was inhibited by knockdown of ATG12 ( Figure 1C) indicating that, although trehalose has other properties that stabilize proteins and organelles (Jain and Roy, 2009) , the effects we see here were due to increased autophagy. Delayed MOMP was also prevented when other autophagy regulators (ATG7, ATG5, and BECN1) were knocked down (Figures S1A-S1C) indicating that this is an autophagydependent effect and not other functions of the targeted genes.
Increased autophagy might delay MOMP by inhibiting signaling at the TRAIL receptor. Indeed, it has been reported that autophagy can degrade activated caspase-8 (Hou et al., 2010) . Trehalose did not noticeably reduce or slow TRAIL-induced caspase-8 or BID cleavage ( Figure 1D ). This suggests that autophagy does not delay MOMP by altering the initial steps in TRAIL receptor signaling. To test this, we monitored the effects of autophagy induction on MOMP induced by Fas Ligand or an artificially dimerized caspase-8 molecule (Oberst et al., 2010) , which both also showed autophagy-dependent delay (Figures S1D and S1E). The lack of delay in BID cleavage and similar delay in MOMP after activation of caspase-8 by other stimuli or even artificial dimerization suggests that autophagy's ability to delay MOMP is due to an effect on mitochondrial permeabilization by tBID rather than an effect on signaling at the TRAIL receptor itself.
Autophagy Regulates PUMA Levels to Control Timing of MOMP To test mechanisms at the mitochondria, we asked if BH3-domain proteins were altered when autophagy was inhibited. Inhibition of autophagy by knockdown of ATG5, ATG7, ATG12, Vps34/PIK3C3, or the selective autophagy mediator p62/ SQSTM1 (Johansen and Lamark, 2011; Noda et al., 2010) all caused an increase in PUMA levels ( Figure 1E ). PUMA increase following ATG knockdown was seen in a variety of tumor cell lines of different tissue origin in addition to HeLa cells (Figure S2A) including those with wild-type or mutant p53. This effect was selective and other BH3 proteins (e.g., BAD, BIM, and NOXA) showed no increase when autophagy was blocked (Figure S2C) . PUMA protein levels might increase after ATG gene knockdown because autophagy directly degrades PUMA or because autophagy degrades something else that inhibits PUMA expression. We examined PUMA mRNA and found that knockdown of essential autophagy regulators and p62/SQSTM1 could increase PUMA mRNA levels suggesting that an indirect mechanism applies. These effects were seen in HeLa cells, which have low levels of p53 and in MDA MB 231 cells (Figure S2B) , which have mutant p53. These data suggest that the mechanism is due to modulation of constitutive PUMA expression not through induced PUMA transcription as occurs in response to p53 activators. Because efficient MOMP requires that proteins like tBID cooperate with PUMA (Chipuk et al., 2008; Chipuk and Green, 2009 ), we next determined the effect of PUMA knockdown on the timing of MOMP after TRAIL treatment. PUMA small hairpin RNA (shRNA) was sufficient to delay MOMP similarly to that seen with trehalose treatment, and this delay was not extended if the PUMA knockdown cells were also treated with trehalose ( Figure 1F ).
Higher Autophagy and PUMA Degradation Allows Cellular Recovery after MOMP Cell contraction and breakup usually occurs in less than 5 min after MOMP has taken place (Albeck et al., 2008) . Consistent with this, control cells where no autophagy manipulation was applied usually contracted quickly after MOMP so that within 20 min the vast majority of cells had a surface area less than 60% of their area immediately before MOMP. However, some cells contract more slowly, and, when autophagy was stimulated with trehalose, it was more common for dying cells to take longer to contract after MOMP as measured by this metric (Figure 2A ). This effect was reversed by knockdown of ATG5 or ATG7 (Figure 2B) indicating that these effects were also autophagy dependent. Surprisingly, continued imaging showed that, although, as expected, most cells underwent MOMP, fast contraction, and then death ( Figure 2C ), cells undergoing slow contraction after MOMP could sometimes recover and display a normal morphology ( Figure 2D ). To test if these effects were due to autophagy's ability to degrade PUMA, we assessed ''slow'' death in PUMA knockdown cells. Figure 3A shows that PUMA (legend continued on next page) knockdown alone, like autophagy induction, increases the number of cells displaying slow contraction after incomplete MOMP. Moreover, continued monitoring demonstrated that these cells (in the absence of any artificial caspase inhibition) could recover normal morphology and even divide afterward ( Figure 3B ; Movies S1 and S2).
The previous experiments were performed with doses of TRAIL high enough to ensure that MOMP eventually occurred in all or almost all the cells. However, if these mechanisms affect the long-term viability of cells, they would be expected to manifest as modulation of the response to different doses of TRAIL. Therefore, we continuously monitored long-term survival in mixed populations of isogenic HeLa cells with specific knockdowns that were marked with GFP-NLS or Cherry-NLS tags and treated with different doses of TRAIL. As expected, knockdown of BID completely prevented TRAIL-induced apoptosis ( Figure 4A ). PUMA knockdown did not prevent apoptosis but did reduce its efficiency as shown by consistent increased viability at different doses of TRAIL ( Figure 4B ). This effect was selective for PUMA because knockdown of another BH3 protein (NOXA) did not affect cell viability ( Figure S3 ). Inhibition of autophagy by knockdown of ATG7 ( Figure 4C ) or Vps34/PIK3C3 (Figure 4D) had the opposite effect as knockdown of PUMA and sensitized to apoptosis indicating a protective effect of autophagy. Importantly, autophagy's protective effect as shown by sensitization to apoptosis upon knockdown of ATG7 ( Figure 4E) or ATG12 ( Figure 4F ) was abolished by PUMA knockdown. Consistent with a modulatory role, protection against potentiation by autophagy inhibition by PUMA depletion was less pronounced when higher doses of TRAIL were used. Thus, TRAIL-induced apoptosis is, as expected, completely dependent on BID, but the efficiency of BID-induced MOMP and subsequent apoptosis are modulated by PUMA. Additionally, the ability of autophagy to selectively regulate PUMA levels explains how autophagy protects against apoptosis and modulates the apoptotic threshold. This effect also occurred in TRAIL-treated MDA MB 231 cells ( Figure S4C ). PUMA knockdown also partially rescued from the potentiation of death induced by autophagy inhibition in response to the general apoptosis inducer staurosporine in both HeLa (Figures S4A  and S4B ) and MDA MB 231 cells ( Figure S4C ). These data suggest that this mechanism applies generally during canonical mitochondrial apoptosis but that when stimuli, such as staurosporine, that are not pure apoptosis inducers like TRAIL are used, protection by PUMA knockdown is reduced.
BCL-family proteins stimulate or inhibit autophagy and apoptosis, and these activities are at the center of the mutual regulation of these two processes by each other. For example, antiapoptotic BCL family proteins like BCL-2 and BCL-xL inhibit autophagy (Pattingre et al., 2005) . BH3-only proteins such as BAD (Maiuri et al., 2007a) , NOXA (Elgendy et al., 2011) , or PUMA (Zhang et al., 2012) can activate autophagy, whereas others such as BIM inhibit autophagy (Luo et al., 2012) showing that autophagy is both positively and negatively regulated by proapoptotic BH3 proteins. PUMA has been reported to regulate mitophagy through a Bax-dependent mechanism (Yee et al., 2009) ; this activity is different from that observed here because it appears to promote rather than inhibit apoptosis. Our results expand this picture by showing that autophagy regulates BH3 protein function in canonical apoptosis through a p62-dependent mechanism that selectively and likely indirectly controls PUMA levels. It is known that PUMA can synergize with activator BH3 proteins such as BID to promote rapid and efficient MOMP followed quickly by complete apoptosis (Chipuk et al., 2008; Chipuk and Green, 2009) . We propose that this mechanism is exploited to allow autophagy to inhibit apoptosis. Constitutive PUMA expression is kept low by selective autophagy through an indirect mechanism, which ultimately affects PUMA mRNA, and this allows changes in PUMA levels to regulate the kinetics and efficiency of MOMP. This mechanism provides a way for autophagy to modulate the rate-limiting step in apoptosis. Moreover, when MOMP does happen in cells with low PUMA, the process is inefficient, and cells are more likely to undergo a slow contraction following caspase activation that is different from that seen in the majority of cells where MOMP is rapidly followed by complete apoptosis and breakup of the cell. Surprisingly, some of these slow cells can recover and even go on to divide. This identifies a mechanism by which autophagy can directly control the core apoptosis machinery and suggests that autophagy's ability to regulate PUMA levels controls synergy with MOMP activators like BID to regulate the apoptotic threshold that determines cell fate.
EXPERIMENTAL PROCEDURES Cell Culture and Reagents
Tumor cell lines cells were cultured in media recommended by ATCC and maintained at 37 C, 5% CO 2 . hTRAIL/TNFSF10 was obtained from R&D Systems and used at a final concentration of 25 ng/ml or as indicated. or pmCherry-LC3 were generated by transfection with Trans-IT-LT1 and hygromycin selection. Small interfering RNA (siRNA) and shRNA knockdowns were performed using SMARTpool:ON TARGET PLUS and pLKO.1 shRNA lentiviruses (sequences are in Supplemental Experimental Procedures). After infection, cells transduced with shRNA lentivirus were allowed to grow and passaged only three times before being discarded to avoid selection for loss of ATG gene knockdown-mediated inhibition of autophagy (Staskiewicz et al., 2013) .
Time-Lapse Video Microscopy and Image Analysis
Time-lapse movies were generated using a Zeiss Axiovert 100 fluorescence microscope enclosed in an environmental chamber (Carl Zeiss) at 103, 323, or 403 magnification. Images were captured with a Hamamatsu Orca CCD camera every 4-6 min using Volocity imaging software (PerkinElmer). Cells were grown in either 6-well plates or 24-well plates (Costar Incorporated and MatTek). IMS-RP release was analyzed visually and by using Volocity software to measure the timing of the drop in SD of the mean red fluorescence intensity when the fluorescent signal changed from more punctate mitochondrial IMS-RP fluorescence to diffuse cytoplasmic fluorescence after mitochondrial outer membrane permeabilization. The area of each cell was determined using Volocity software. Time-lapse movies in Figure 2A were generated using a Nikon A1R-Si spectral imaging confocal microscope equipped with an environmental chamber (Nikon) at 403 magnification. Images were taken every 4 min using ImageJ software. In Figure 4 and in Figure S3 , quantitative live cell imaging to assess long-term viability was performed using an IncuCyte Zoom imaging system (Essen Biosciences). Images were obtained every 4 hr using a 103 objective. Live cell content was determined using the custom parameters for measuring cell confluence and/or fluorescence. For fluorescence imaging of mixed cultures, HeLa cells expressing nuclear GFP or mCherry were used expressing control or targeted shRNA lentiviruses. 
